A Randomized, Double Blind, Placebo-Controlled, Multicenter Trial of Allisartan Isoproxil for treatment of Essential Hypertensive Population at Low-Medium Risk.

Trial Profile

A Randomized, Double Blind, Placebo-Controlled, Multicenter Trial of Allisartan Isoproxil for treatment of Essential Hypertensive Population at Low-Medium Risk.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Allisartan (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Actual end date changed from Nov 2009 to Jan 2010as reported by Chinese Clinical Trial Register record.
    • 09 Jan 2012 Actual initiation date changed from 1Jul 2009 to 1 Apr 2009 as reported by Chinese Clinical Trial Register.
    • 09 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top